Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease

Coronary Artery Disease

Volumn 22, Issue 5, 2011, Pages 352-358

  Suzuki, Takayuki ^a   Nozawa, Takashi ^a   Fujii, Nozomu ^a   Sobajima, Mitsuo ^a   Ohori, Takashi ^a   Shida, Takuya ^a   Matsuki, Akira ^a   Kameyama, Tomoki ^a   Inoue, Hiroshi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

computed tomography; coronary artery disease; renin angiotensin system; thoracic aorta

Indexed keywords

ATORVASTATIN; CANDESARTAN; CONTRAST MEDIUM;

ARTERY WALL; ARTICLE; BLOOD VESSEL PARAMETERS; CARDIAC PATIENT; CLINICAL ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; DESCENDING AORTA; FEMALE; FOLLOW UP; HUMAN; LEFT CORONARY ARTERY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; RIGHT CORONARY ARTERY; THORACIC AORTA; THORACIC DESCENDING AORTA; TOTAL VASCULAR AREA; TREATMENT DURATION; VESSEL WALL AREA;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BENZIMIDAZOLES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL; CORONARY ARTERY DISEASE; DINOPROST; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; LONGITUDINAL STUDIES; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PYRROLES; TETRAZOLES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79960700220     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328346b8a2     Document Type: Article

References (27)

1. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, SasielaWJ, Tsai J, et al.; for the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352:29-38. (Pubitemid 40075678)
2. Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors. Circulation 2004; 109 (Suppl II):II-18-II-26.
3. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotropy in humans. Differential effects of statins and ezetimibe of Rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2009; 119:131-138.
4. Hayek T, Attias J, Coleman R, Brodsky S, Smith J, Breslow JL, et al. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res 1999; 44:579-587. (Pubitemid 30012061)
5. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure; randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355:1582-1587. (Pubitemid 30240502)
6. Morawietz H, Erbs S, Holtz J, Schubert A, Krekler M, Goettsch W, et al. Endothelial protection, AT1 blockade and cholesterol-dependent oxidative stress. The EPAS trial. Circulation 2006; 114 (Suppl I):I-296-I-301. (Pubitemid 44297166)
7. Waseda K, Ozaki Y, Takashima H, Ako J, Yasukawa T, Ismail T, et al. Impact of angiotensin II receptor blockers on the progression and regression of coronary atherosclerosis. An intravascular ultrasound study. Circ J 2006; 70:1111-1115. (Pubitemid 44386988)
8. Koh KK, Son JW, Ahn JY, Kim DS, Jin DK, Kim HS, et al. Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension 2004; 44:180-185. (Pubitemid 39014236)
9. Ceriello A, Assaloni R, Ros RD, Maier A, Piconi L, Quagliaro L, et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005; 111:2518-2524. (Pubitemid 40696141)
10. Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H, Iwai M. Fluvastatin enhances the inhibitory effects of a selective angiotensin II receptor blocker, valsartan, on vascular neointimal formation. Circulation 2003; 107:106-112. (Pubitemid 36070941)
11. Liu L, Zhao SP, Zhou HN, Li QZ, Li JX. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension. J Cardiovasc Pharmacol 2007; 50:50-55. (Pubitemid 47220446)
12. Leber AW, Knez A, Becker A, Becker C, von Ziegler F, Nikolaou K, et al. Accuracy of mutidetector spiral computed tomography in identifying and differentiating the composition of coronary atherosclerotic plaques: a comparative study with intracoronary ultrasound. J Am Coll Cardiol 2004; 43:1241-1247. (Pubitemid 38452602)
13. Kuettner A, Kopp AF, Schroeder S, Reiger T, Brum J, Meisner C, et al. Diagnostic accuracy of multidetector computed tomography coronary angiography in patients with angiographically proven coronary artery disease. J Am Coll Cardiol 2004; 43:831-839. (Pubitemid 38296484)
14. Motoyama S, Kondo T, Sarai M, Sugiura A, Harigaya H, Sato T, et al. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol 2007; 50:319-326. (Pubitemid 47058884)
15. Choi BJ, Kang DK, Tahk SJ, Choi SY, Yoon MH, Lim HS, et al. Comparison of 64-slice multidetector computed tomography with spectral analysis of intravascular ultrasound backscatter signals for characterizations of noncalcified coronary arterial plaques. Am J Cardiol 2008; 102:988-993.
16. Leber AW, Becker A, Knez A, von Ziegler F, Sirol M, Nikolaou K, et al. Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system. J Am Coll Cardiol 2006; 47:672-677. (Pubitemid 43170862)
17. Leber AW, Knez A, Ziegler F, Becker A, Nikolaou K, Paul S, et al. Quantification of obstructive and non-obstructive coronary lesions by 64-slice computed tomography. J Am Coll Cardiol 2005; 46:147-154.
18. Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360:7-16.
19. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al.; for the Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-28.
20. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al.; for the REVERSAL investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004; 291:1071-1080. (Pubitemid 38541684)
21. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al.; for the ASTEROID investigators. Effect of very high-intensity stain therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 2006; 295:1556-1565.
22. Johnstone M, Perez AS, Nasser I, Stewart R, Vaidya A, Ammary FA, et al. Angiotensin receptor blockade with candesartan attenuates atherosclerosis, plaque disruption, and macrophage accumulation within the plaque in a rabbit model. Circulation 2004; 110:2060-2065. (Pubitemid 39331922)
23. Li Z, Iwai M,Wu L, Liu HW, Chen R, Jinno T, et al. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension 2004; 44:758-763. (Pubitemid 39435250)
24. Chen J, Li D, Schaefer R, Mehta JL. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherosclerosis. Studies with the combined use of the rosuvastatin and candesartan. Atherosclerosis 2006; 184:295-301. (Pubitemid 43049713)
25. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340:14-22. (Pubitemid 29024679)
26. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326:381-386.
27. Ayaori M, Momiyama Y, Fayad ZA, Yonemura A, Ohmori R, Kihara T, et al. Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia. Atherosclerosis 2008; 196:425-433.